WallStreetZenWallStreetZen

NASDAQ: NTLA
Intellia Therapeutics Inc Stock

$24.63+1.48 (+6.39%)
Updated Jul 11, 2024
NTLA Price
$24.63
Fair Value Price
-$4.89
Market Cap
$2.38B
52 Week Low
$19.37
52 Week High
$46.50
P/E
-4.6x
P/B
2.29x
P/S
49.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$52.60M
Earnings
-$485.50M
Gross Margin
100%
Operating Margin
-922.94%
Profit Margin
-922.9%
Debt to Equity
0.22
Operating Cash Flow
-$405M
Beta
1.71
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

NTLA Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NTLA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NTLA ($24.63) is overvalued by 603.4% relative to our estimate of its Fair Value price of -$4.89 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NTLA ($24.63) is not significantly undervalued (603.4%) relative to our estimate of its Fair Value price of -$4.89 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NTLA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NTLA due diligence checks available for Premium users.

Be the first to know about important NTLA news, forecast changes, insider trades & much more!

NTLA News

Valuation

NTLA fair value

Fair Value of NTLA stock based on Discounted Cash Flow (DCF)
Price
$24.63
Fair Value
-$4.89
Undervalued by
603.40%
NTLA ($24.63) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NTLA ($24.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NTLA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NTLA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.6x
Industry
-14.46x
Market
31.84x

NTLA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.29x
Industry
6.37x
NTLA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NTLA's financial health

Profit margin

Revenue
$28.9M
Net Income
-$107.4M
Profit Margin
-371.3%
NTLA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NTLA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.3B
Liabilities
$223.5M
Debt to equity
0.22
NTLA's short-term assets ($884.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NTLA's short-term assets ($884.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NTLA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NTLA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$120.7M
Investing
$5.9M
Financing
$60.0M
NTLA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NTLA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NTLA$2.38B+6.39%-4.60x2.29x
IOVA$2.36B+8.48%-4.69x3.47x
KYMR$2.39B+7.59%-15.54x3.36x
VCEL$2.40B+8.71%N/A10.27x
CGON$2.30B+5.03%N/A4.04x

Intellia Therapeutics Stock FAQ

What is Intellia Therapeutics's quote symbol?

(NASDAQ: NTLA) Intellia Therapeutics trades on the NASDAQ under the ticker symbol NTLA. Intellia Therapeutics stock quotes can also be displayed as NASDAQ: NTLA.

If you're new to stock investing, here's how to buy Intellia Therapeutics stock.

What is the 52 week high and low for Intellia Therapeutics (NASDAQ: NTLA)?

(NASDAQ: NTLA) Intellia Therapeutics's 52-week high was $46.50, and its 52-week low was $19.37. It is currently -47.03% from its 52-week high and 27.16% from its 52-week low.

How much is Intellia Therapeutics stock worth today?

(NASDAQ: NTLA) Intellia Therapeutics currently has 96,475,421 outstanding shares. With Intellia Therapeutics stock trading at $24.63 per share, the total value of Intellia Therapeutics stock (market capitalization) is $2.38B.

Intellia Therapeutics stock was originally listed at a price of $22.10 in May 6, 2016. If you had invested in Intellia Therapeutics stock at $22.10, your return over the last 8 years would have been 11.45%, for an annualized return of 1.36% (not including any dividends or dividend reinvestments).

How much is Intellia Therapeutics's stock price per share?

(NASDAQ: NTLA) Intellia Therapeutics stock price per share is $24.63 today (as of Jul 11, 2024).

What is Intellia Therapeutics's Market Cap?

(NASDAQ: NTLA) Intellia Therapeutics's market cap is $2.38B, as of Jul 12, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Intellia Therapeutics's market cap is calculated by multiplying NTLA's current stock price of $24.63 by NTLA's total outstanding shares of 96,475,421.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.